2-Hydroxybenzylamine Clinical Trials

Size	Price	Qty
25mg	USD 97
1g	USD 490

Clinical Trials

Multiple clinical trials are evaluating 2-hydroxybenzylamine in Phase I and Phase II studies targeting cardiovascular, metabolic, and age-related conditions, including familial hypercholesterolemia, catheter ablation-associated atrial fibrillation, salt sensitivity of blood pressure, and cognitive decline. Sponsored by academic institutions, medical centers, and biotechnology companies with federal support, these protocols range from completed safety and brain-penetrance assessments in healthy volunteers to active, recruiting, and planned interventions in target patient cohorts.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07602166	NOT_YET_RECRUITING	Salt Sensitivity of Blood Pressure; High Blood Pressure; Inflammation; Renin-Angiotensin-Aldosterone System	Vanderbilt University Medical Center	2026-09	PHASE2
NCT06432166	NOT_YET_RECRUITING	Alzheimer Disease; Mild Cognitive Impairment	MTI Biotech Inc	2026-09-01	PHASE1; PHASE2
NCT04941599	RECRUITING	Familial Hypercholesterolemia	Vanderbilt University Medical Center	2024-02-14	PHASE2
NCT07419633	RECRUITING	Muscle; Cognitive Functioning; Geriatric; Ageing and Geriatric Health; Ageing	McGill University Health Centre/Research Institute of the McGill University Health Centre	2026-03-06
NCT04941599	Recruiting	Familial Hypercholesterolemia	Vanderbilt University Medical Center\|National Heart Lung and Blood Institute (NHLBI)	2024-02-14	Phase 2
NCT04433091	COMPLETED	Atrial Fibrillation	Vanderbilt University Medical Center	2020-05-15	PHASE2
NCT03556319	COMPLETED	Older Adults	Metabolic Technologies Inc.	2018-05-23
NCT04433091	Active not recruiting	Atrial Fibrillation	Vanderbilt University Medical Center\|American Heart Association	2020-05-15	Phase 2
NCT03555682	COMPLETED	Healthy Volunteers	Metabolic Technologies Inc.	2018-05-23
NCT03554096	COMPLETED	Healthy Adults	Metabolic Technologies Inc.	2018-05-23
NCT03176940	COMPLETED	Healthy Volunteers	Metabolic Technologies Inc.	2017-08-02

(data from https://clinicaltrials.gov, updated on 2026-07-28)

Check the 2-Hydroxybenzylamine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

2-Hydroxybenzylamine acts as a selective scavenger of dicarbonyl electrophiles such as isolevuglandins, rapidly reacting with these species to prevent the destructive covalent modification of key cellular proteins and lipids. By neutralizing these oxidative intermediates, the compound suppresses downstream inflammatory cascades and lipid peroxidation, thereby enhancing efferocytosis and vascular tissue stability in clinical conditions such as familial hypercholesterolemia and hypertension.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).